Cambridge Cognition

We are a digital neuroscience company developing software products and services to better understand, detect and treat conditions affecting brain health.

[Cambridge Cognition @CANTABconnect]

Can changes in speech patterns be an early indicator of cognitive decline? https://t.co/De7Rd2eRXe

[Cambridge Cognition @CANTABconnect]

These developments represent a significant step forward in our collective mission to fight Alzheimer's disease and dementias. If these topics are relevant to your work, we would love to chat! Find out more here: https://t.co/VlRwIKV96p

[Cambridge Cognition @CANTABconnect]

At AAIC25, we will be presenting the poster "Sensitivity of Cognitive Outcome Measures to Plasma p-tau217 in Mild Cognitive Impairment in the AI-Mind study," by Alex Kaula. Sign up to be the first to download this research: https://t.co/s6lOAwHoxD

[Cambridge Cognition @CANTABconnect]

Check out our latest research at #AAIC25. This poster presents comprehensive data on the development of composite speech biomarkers, rigorously validated for use as a novel endpoint in MCI/AD clinical trials. Find out more: https://t.co/FvYNMRgTdV

[Cambridge Cognition @CANTABconnect]

Speech biomarkers for MCI/AD - presenting analytical and clinical validation in Dutch, Danish, German & Spanish! Discover the impact of our global validation research presented at AAIC 2025. Dive deeper: https://t.co/bGVHZaf99F

[Cambridge Cognition @CANTABconnect]

Ensuring Data Reliability in High-Frequency Remote Assessments: Sign up to be the first to receive our research and find out how we are building confidence in remote data collection: https://t.co/UGavx2VfTk

#AAIC2025 #DigitalBiomarkers #Alzheimers #Psychometrics #ClinicalTrials

[Cambridge Cognition @CANTABconnect]

We're thrilled to announce! We're presenting 4 exciting posters at #AAIC25! 🧠 Discover our latest science and get the insights shaping #CNS drug development:
https://t.co/1qIsdXU0GP #Alzheimers #DigitalBiomarkers #ClinicalTrials

[Cambridge Cognition @CANTABconnect]

We're looking forward to seeing you tomorrow at the Digital Biomarkers in Clinical Trials Summit!

#digitalbiomarkers #digitalhealth #clinicaltrials #cognition #pharmaceuticalresearch

[Cambridge Cognition @CANTABconnect]

Join us at 11:20am on 25th June to hear real world examples of how digital assessments can improve patient engagement.

Register now to secure your place: https://t.co/tCNRm8Hnqc

#DigitalBiomarkers #ClinicalTrials #DigitalHealth #PharmaInnovation

[Cambridge Cognition @CANTABconnect]

We're looking forward to this key event for leaders and innovators in #digitalhealth and #pharmaceuticalresearch, exploring evolving role of #digitalbiomarkers in #clinicaltrials to drive the acceleration of drug development. Secure your spot: https://t.co/FllOkmixj1

[Cambridge Cognition @CANTABconnect]

Sponsored by Biogen in collaboration with Apple, he study enrolled a representative sample of 23,004 participants across the United States and relied on Cambridge Cognition's CANTAB® platform for the core cognitive assessment. Read more here: https://t.co/U8cVMg7hr6

[Cambridge Cognition @CANTABconnect]

Michael Spilka shares his key takeaways from this year's #Schizophrenia International Research Society Congress, and the key findings on his poster presentations.

Read more: https://t.co/fQARYtJOPg

[Cambridge Cognition @CANTABconnect]

ICYMI: Stay up-to-date on the future of dementia research and the key shifts that could redefine clinical trials and patient care in neurodegenerative diseases: https://t.co/uGhQDFDkag

#DementiaResearch #CNSDrugDevelopment #ClinicalTrials #Innovation #FutureofMedicine

[Cambridge Cognition @CANTABconnect]

The selection of the right cognitive assessment isn't just a methodological choice; it's a foundational element that underpins the reliability and impact of your clinical trial data.

➡️ Explore the factors to consider and the benefits of each approach: https://t.co/aTU9qcs1LS

[Cambridge Cognition @CANTABconnect]

AD/PD kicks off today with a packed agenda!
🥇Get our posters delivered to your inbox here: https://t.co/HJG0FnPltV

[Cambridge Cognition @CANTABconnect]

New Mild Cognitive Impairment insights! 💡
Nick Taptiklis's #ADPD2025 poster reveals novel reaction time measures from CANTAB® PAL. Discover how timing-based data enhances understanding of MCI. Download now! ➡️ https://t.co/ywPuNRiveA
#MCI #Neuroscience #Alzheimers #Parkinsons

[Cambridge Cognition @CANTABconnect]

The ability to conduct reliable cognitive testing remotely is crucial for expanding access and efficiency in studies related to aging and neurodegenerative diseases. Get the poster here! https://t.co/66kxkeDTL1

#Alzheimers #Parkinsons #ClinicalTrials #Neuroscience

[Cambridge Cognition @CANTABconnect]

Join our Chief Scientist for her poster "Novel Digital Measures of Reaction Time and Drawing Speed" from the @ideafastproject. Discover how our digital tools can provide unique insights into movement & accuracy in neurodegenerative disorders: https://t.co/ygPwyFPS5q

[Cambridge Cognition @CANTABconnect]

Does computerised cognitive testing have sufficient sensitivity for assessing cognitive impairment associated with #schizophrenia in clinical trials?

Get the research: https://t.co/7d5jubgtJ4

#SIRS2025 #SchizophreniaResearch #ClinicalTrials #DigitalHealth

[Cambridge Cognition @CANTABconnect]

Can speech reveal the severity of #schizophrenia symptoms? Find out more: https://t.co/23KBmTzZ7r